<DOC>
	<DOCNO>NCT01496274</DOCNO>
	<brief_summary>This study examine safety , pharmacokinetics efficacy rIX-FP control prevention bleed episode subject previously receive factor replacement therapy hemophilia B .</brief_summary>
	<brief_title>A Safety Efficacy Study Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin ( rIX-FP ) Patients With Hemophilia B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male subject , 12 65 year old Severe hemophilia B ( FIX activity â‰¤ 2 % ) Subjects receive FIX product ( plasmaderived and/or recombinant FIX ) &gt; 150 exposure day ( EDs ) No history FIX inhibitor formation , detectable inhibitor Screening family history inhibitor FIX Written inform consent study participation Ondemand subject , experience minimum average 2 nontrauma induce bleed episode require treatment FIX product previous 6 3 month Known hypersensitivity FIX product hamster protein Known congenital acquire coagulation disorder congenital FIX deficiency HIV positive subject CD4 count &lt; 200/mm3 Low platelet count , kidney liver dysfunction Recent lifethreatening bleed episode</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>